iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Three separate studies reported in 2026 point to ways researchers might undermine hard-to-treat bacteria: interrupting energy production in Mycobacterium abscessus, anticipating how it evades bacteriophages, and disrupting how Pseudomonas aeruginosa loads toxins into its attack system. These are mechanistic and experimental findings, not established treatments or evidence of benefit in patients.
What do the three studies have in common?
They look for vulnerabilities in bacterial survival and attack systems rather than describing a single new antibiotic. Two studies concern M. abscessus, a bacterium that can cause severe lung disease, including in people with cystic fibrosis, and is intrinsically resistant to many commonly used antibiotics. The third examines the type VI secretion system (T6SS) of P. aeruginosa, a system the bacterium uses to inject toxins into other cells.
| Research strand | Pathogen | Process examined | Evidence described |
|---|---|---|---|
| Energy production | M. abscessus | Cytochrome bcc:aa3 oxidase in the electron transport chain | Structural analysis and an experimental inhibitor, ND-011458; a combination experiment with clofazimine was reported by NTU in 2026. |
| Phage resistance | M. abscessus | Surface changes associated with resistance to bacteriophages | Bacterial adaptation under phage pressure and a combination approach reported by A*STAR in 2026. |
| Toxin loading | P. aeruginosa | Assembly of toxin cargo in the T6SS | A molecular mechanism for Hcp-mediated toxin loading, reported by NTU in 2026. |
The shared theme is that a bacterium’s defenses and attack machinery depend on organized biological processes that may be possible to interrupt. The studies differ in pathogen, method and intended application, so they should not be read as competing treatments.
Recommended Free Tools
How could disrupting energy production weaken M. abscessus?
The target: an enzyme in the electron transport chain
The study led by NTU professor Gerhard Grüber examined cytochrome bcc:aa3 oxidase, part of the electron transport chain that helps the bacterium produce ATP. ATP supplies energy for essential cellular activity. Using cryo-electron microscopy, the researchers identified a substrate-binding pocket in the enzyme’s cytochrome b subunit and designed ND-011458, an experimental compound intended to fit that pocket and inhibit the enzyme.
#1 Best Overall
The rationale is to impair a process that supplies energy not only for basic cell functions but also for bacterial defenses. Grüber described the approach this way: “As the currency of life, ATP delivers the energy for essential processes in M. abscessus, including its defense mechanisms against antibiotics. Silencing the electron transport chain that produces ATP is thus a potential treatment for difficult-to-treat M. abscessus infections that also disables the bacterium.”
What the reported combination result does—and does not—show
NTU’s October 3, 2026 report says ND-011458 used with clofazimine reduced M. abscessus by two logs in four days in the reported experiment. That is an experimental result, not a patient outcome, and it does not establish an approved regimen or clinical efficacy.
The report says a patent was filed and that the researchers were working with U.S.-based Hsiri Therapeutics to license the compound. It does not establish the present status of that licensing effort, whether ND-011458 has entered clinical trials, or whether it is available to patients. The associated paper is Vikneswaran Mathiyazakan et al., “The Mycobacterium abscessus cytochrome bcc:aa3 oxidase structure paves the way for an agent targeting subunit QcrB,” Nature Communications (2026), DOI: 10.1038/s41467-026-70805-5.
Rank #2
How does M. abscessus resist bacteriophages?
Surface changes can make phage recognition harder
Bacteriophages, or phages, are viruses that infect bacteria. In the account of the work from NTU and A*STAR, smooth M. abscessus strains display glycopeptidolipids on their surface. Under phage pressure, some bacteria shifted to a rough form associated with mutations in genes needed to make or transport those lipids. The researchers hypothesize that losing the lipids can prevent phages from binding.
Resistance was not limited to the rough form: some bacteria remained smooth while resisting phages through mutations in other surface-related genes. This matters because a phage may select for bacterial variants that are harder for that same phage to infect, rather than eliminating every bacterium in a population.
Why researchers considered a combination strategy
A*STAR described an approach designed to target both smooth bacteria and emerging rough variants. It performed better than single-phage treatment in the study context. That result supports a design strategy for phage research; it does not show that the combination is generally effective or established as treatment for patients.
Rank #3
The study is Jun Hao Liew et al., “Smooth-to-rough morphotype switching, a mechanism of phage resistance in Mycobacterium abscessus,” Proceedings of the National Academy of Sciences (2026), DOI: 10.1073/pnas.2531197123. A*STAR’s institutional account of the work is dated May 4, 2026. NTU scientist and corresponding author Pablo Bifani said: “These findings reveal an important challenge in developing phage-based therapies. Although phages can effectively eliminate bacteria, they may also inadvertently make infections more difficult to treat, as seen in the ‘rough’ form.”
How does P. aeruginosa load toxins into its T6SS?
Hcp proteins assemble around cargo before firing
The T6SS is a contractile bacterial apparatus used to inject toxins into other cells. In the mechanism described by the NTU report, toxin cargo is first captured by Hcp proteins. Five additional Hcp proteins wrap around the cargo to form a ring; a larger toxin may require two rings. Loaded rings then stack into a tube, which is propelled outward when the system contracts.
Because the tube can carry different toxins, a single firing can deliver more than one effector. NTU research director and co-corresponding author Alain Filloux summarized the system as follows: “This bacterium does not just fire a single toxin. It loads a cocktail of toxins into a microscopic speargun and fires them in one strike, allowing it to attack different targets, including beneficial bacteria that normally live in the body, as well as the host’s own defense cells.”
Rank #4
Possible applications remain proposals
Understanding how cargo is loaded could help researchers investigate whether that step can be blocked to disarm the system. The authors also discuss a possible future use of engineered harmless bacteria carrying T6SS cargo against invading bacteria. Neither idea is described in the report as an available intervention or as having demonstrated clinical benefit.
Associate professor Tiago Dias da Costa of Imperial College London, who co-led the study, said: “What is exciting about this work is that we can now see, at near-atomic detail, how a bacterial toxin is physically captured and enclosed inside the building blocks of the T6SS.” The paper is Patricia Paracuellos et al., “Molecular basis of type VI secretion system effector loading,” Nature Microbiology (2026), DOI: 10.1038/s41564-026-02363-x.
How close are these findings to treatment?
The three strands are at research stages described through structural work, bacterial adaptation under phage pressure and a molecular mechanism. The reports establish no patient efficacy finding or marketed product arising from these studies. ND-011458 is experimental; the phage combination is a research approach; and blocking T6SS loading or using engineered bacteria are prospective ideas.
Best Value
- Microbiology and Virology design. This design with Bacteriophage Virology and "Just watch - One Day I'll Go Viral for everyone Teaching Biology and loves Microbiology and biochemist
- Gift for Science Teacher an people who like Cell Biology and love to research viruses, cells, bacteria and genes.
- Lightweight, Classic fit, Double-needle sleeve and bottom hem
For context, A*STAR’s May 4, 2026 report states that one in six bacterial infections worldwide is resistant to antibiotics. NTU’s October 3, 2026 report cites a World Health Organization estimate of 10 million deaths a year by 2050. These are contextual figures attributed to those reports, not outcomes measured by the three studies.
The energy-production and T6SS paper details and summaries above are reported by NTU Singapore in its October 3, 2026 account; the phage study has additional institutional detail from A*STAR. The available account does not establish independent replication or clinical testing of the proposed applications.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →
